Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML
- Status
- SUSPENDED
- Phase
- PHASE1
Clinical Trials Related to Venetoclax
Related studies linked through entity extraction aliases.
Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD
- Status
- RECRUITING
- Phase
- PHASE2
Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML
- Status
- RECRUITING
- Phase
- PHASE2
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
- Status
- RECRUITING
- Phase
- PHASE1
Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment
- Status
- RECRUITING
- Phase
- PHASE3
Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL
- Status
- RECRUITING
- Phase
- NA
Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL
- Status
- RECRUITING
- Phase
- NA
Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
A Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated Leukemias
- Status
- RECRUITING
- Phase
- PHASE1
Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Status
- SUSPENDED
- Phase
- PHASE1
Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML
- Status
- RECRUITING
- Phase
- PHASE2
Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia
- Status
- RECRUITING
- Phase
- PHASE1
Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Mitoxantrone Hydrochloride Liposome Injection, Cytarabine Combined With Venetoclax in the Treatment of R/R AML
- Status
- RECRUITING
- Phase
- PHASE2